Stock Scorecard
Stock Summary for Celularity Inc - Class A (CELU) - $1.12 as of 4/24/2026 12:58:17 PM EST
Total Score
7 out of 30
Safety Score
12 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CELU
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CELU
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CELU
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CELU
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CELU (12 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CELU
Financial Details for CELU
Company Overview |
|
|---|---|
| Ticker | CELU |
| Company Name | Celularity Inc - Class A |
| Country | USA |
| Description | Celularity Inc. is an innovative biotechnology company dedicated to pioneering regenerative medicine through its proprietary cellular products derived from the placenta. The firm boasts a robust pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, targeted at improving treatment efficacy and minimizing complications for cancer and other serious diseases. Supported by a seasoned leadership team and strategic collaborations, Celularity is strategically positioned to meet substantial unmet medical needs, thereby establishing itself as a pivotal entity in the dynamic landscape of advanced therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.12 |
| Price 4 Years Ago | 12.90 |
| Last Day Price Updated | 4/24/2026 12:58:17 PM EST |
| Last Day Volume | 75,038 |
| Average Daily Volume | 41,692 |
| 52-Week High | 4.35 |
| 52-Week Low | 1.01 |
| Last Price to 52 Week Low | 10.89% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 38.00 |
| Sector PE | 104.92 |
| 5-Year Average PE | 22.41 |
| Free Cash Flow Ratio | 0.00 |
| Industry Free Cash Flow Ratio | 17.57 |
| Sector Free Cash Flow Ratio | 27.40 |
| Current Ratio Most Recent Quarter | 0.16 |
| Total Cash Per Share | 0.00 |
| Book Value Per Share Most Recent Quarter | -0.71 |
| Price to Book Ratio | 9.89 |
| Industry Price to Book Ratio | 5.92 |
| Sector Price to Book Ratio | 10.48 |
| Price to Sales Ratio Twelve Trailing Months | 0.80 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.76 |
| Sector Price to Sales Ratio Twelve Trailing Months | 25.13 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 28,837,800 |
| Market Capitalization | 32,298,336 |
| Institutional Ownership | 12.97% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -61.30% |
| Annual Earnings Growth | 70.51% |
| Reported EPS 12 Trailing Months | -3.33 |
| Reported EPS Past Year | -2.50 |
| Reported EPS Prior Year | -2.65 |
| Net Income Twelve Trailing Months | -74,183,000 |
| Net Income Past Year | -57,892,000 |
| Net Income Prior Year | -196,295,000 |
| Quarterly Revenue Growth YOY | -43.20% |
| 5-Year Revenue Growth | 20.72% |
| Operating Margin Twelve Trailing Months | -243.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 120,000 |
| Total Cash Past Year | 738,000 |
| Total Cash Prior Year | 227,000 |
| Net Cash Position Most Recent Quarter | -36,372,000 |
| Net Cash Position Past Year | -35,189,000 |
| Long Term Debt Past Year | 35,927,000 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 36,492,000 |
| Equity to Debt Ratio Past Year | 0.20 |
| Equity to Debt Ratio Most Recent Quarter | -1.23 |
| Total Stockholder Equity Past Year | 8,837,000 |
| Total Stockholder Equity Prior Year | 40,960,000 |
| Total Stockholder Equity Most Recent Quarter | -20,094,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -2,137,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.07 |
| Free Cash Flow Past Year | -6,562,000 |
| Free Cash Flow Prior Year | -42,733,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.01 |
| MACD Signal | 0.01 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.70 |
| RSI | 0.00 |
| 50-Day SMA | 1.93 |
| 150-Day SMA | 2.68 |
| 200-Day SMA | 6.32 |
System |
|
| Modified | 4/24/2026 8:06:58 PM EST |